<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35467483</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Preparation of baicalin-loaded ligand-modified nanoparticles for nose-to-brain delivery for neuroprotection in cerebral ischemia.</ArticleTitle>
        <Pagination>
          <StartPage>1282</StartPage>
          <EndPage>1298</EndPage>
          <MedlinePgn>1282-1298</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2064564</ELocationID>
        <Abstract>
          <AbstractText>Neuroprotection in cerebral ischemia (CI) has received increasing attention. However, efficient delivery of therapeutic agents to the brain remains a major challenge due to the complex environment of the brain. Nose-to-brain-based delivery is a promising approach. Here, we optimized a nanocarrier formulation of neuroprotective agents that can be used for nose-to-brain delivery by obtaining RVG29 peptide-modified polyethylene glycol-polylactic acid-co-glycolic acid nanoparticles (PEG-PLGA RNPs) that have physicochemical properties that lead to stable and sustained drug release and thereby improve the bioavailability of neuroprotective agents. The brain-targeting ability of PEG-PLGA RNPs administered through nasal inhalation was verified in a rat model of CI. It was found that delivery to the whole brain can be achieved with little delivery to the peripheral circulation. Baicalin (BA) was selected as the neuroprotective agent for delivery. After intranasal administration of BA-PEG-PLGA RNPs, the neurological dysfunction of rats with ischemic brain injury was significantly alleviated, the cerebral infarction area was reduced, and nerve trauma and swelling were relieved. Furthermore, it was demonstrated that the neuroprotective effects of BA in a rat model of CI may be mediated by inhibition of inflammation and alleviation of oxidative stress. The immunohistochemical results obtained after treatment with nanoparticles loaded with BA showed that Nrf2/HO-1 was activated in the area in which ischemic brain damage had occurred and that its expression was significantly higher in the group treated with BA-PEG-PLGA RNPs than in the other groups. The ELISA results showed that the levels of IL-1β, IL-6, and TNF-α were abnormally increased in the serum of rats with cerebral ischemia. After treatment with BA-loaded nanoparticles, IL-1β, IL-6, and TNF-α levels decreased significantly. Oxidative stress was alleviated; the levels of glutathione and superoxide dismutase increased; and the levels of reactive oxygen species and malondialdehyde decreased, in animals to which BA-PEG-PLGA RNPs were delivered by intranasal inhalation. In conclusion, BA-PEG-PLGA RNPs can effectively deliver BA to rats and thereby exert neuroprotective effects against CI.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xinxin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chinese Medicine, Changchun University of Chinese Medicine, ChangChun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Shuling</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Hospital of Changchun University of Chinese Medicine, ChangChun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Chun</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Hospital of Changchun University of Chinese Medicine, ChangChun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tieshu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chinese Medicine, Changchun University of Chinese Medicine, ChangChun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Lihua</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Hospital of Changchun University of Chinese Medicine, ChangChun, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>347Q89U4M5</RegistryNumber>
          <NameOfSubstance UI="C038044">baicalin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
          <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002545" MajorTopicYN="Y">Brain Ischemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Nose-to-brain</Keyword>
        <Keyword MajorTopicYN="N">baicalin</Keyword>
        <Keyword MajorTopicYN="N">cerebral ischemia</Keyword>
        <Keyword MajorTopicYN="N">nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">rabies virus glycoprotein 29</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>12</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35467483</ArticleId>
        <ArticleId IdType="pmc">PMC9045769</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2064564</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ashraf O, Nasr M, Nebsen M, et al.  (2018). In vitro stabilization and in vivo improvement of ocular pharmacokinetics of the multi-therapeutic agent baicalin: Delineating the most suitable vesicular systems. Int J Pharm
539: 83–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29374518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattamisra SK, Shak AT, Xi LW, et al.  (2020). Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease. Int J Pharm
579:119148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32084576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. (2018). Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm
128:337–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29733950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chouchani ET, Pell VR, Gaude E, et al.  (2014). Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature
515: 431–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4255242</ArticleId>
            <ArticleId IdType="pubmed">25383517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung EP, Cotter JD, Prakapenka AV, et al.  (2020). Targeting small molecule delivery to the brain and spinal cord via intranasal administration of rabies virus glycoprotein (RVG29)-Modified PLGA nanoparticles. Pharmaceutics
12 (2):93.</Citation>
        </Reference>
        <Reference>
          <Citation>Cook RL, Householder KT, Chung EP, et al.  (2015). A critical evaluation of drug delivery from ligand modified nanoparticles: confounding small molecule distribution and efficacy in the central nervous system. J Control Release
220: 89–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4688251</ArticleId>
            <ArticleId IdType="pubmed">26471392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowe TP, Greenlee M, Kanthasamy AG, Hsu WH. (2018). Mechanism of intranasal drug delivery directly to the brain. Life Sci
195:44–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29277310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Oliveira JE, Santos L, Salomao MA, et al.  (2020). Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating. Drug Deliv Transl Res
10: 1688–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32613550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du J, Yin G, Hu Y, et al.  (2020). Coicis semen protects against focal cerebral ischemia-reperfusion injury by inhibiting oxidative stress and promoting angiogenesis via the TGFβ/ALK1/Smad1/5 signaling pathway. Aging (Albany NY)
13:877–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7835068</ArticleId>
            <ArticleId IdType="pubmed">33290255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duffy KR, Pardridge WM, Rosenfeld RG (1988). Human blood-brain barrier insulin-like growth factor receptor. Metabolism
37:136–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2963191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gan L, Li Z, Lv Q, Huang W. (2019). Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinson’s disease model. Int J Pharm
567:118449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31226473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S, Wang W, Wang S, et al.  (2019). Multifunctional biomimetic nanoparticles loading baicalin for polarizing tumor-associated macrophages. Nanoscale
11:20206–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31621735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Y, Chu X, Cui L, et al.  (2020). Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems. Drug Deliv
27:502–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7170363</ArticleId>
            <ArticleId IdType="pubmed">32228100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao R, Sun B, Yang L, et al.  (2020). RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery. Drug Deliv
27:772–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7269067</ArticleId>
            <ArticleId IdType="pubmed">32400219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoekman JD, Ho RJ. (2011). Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg
113:641–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3161132</ArticleId>
            <ArticleId IdType="pubmed">21709146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Q, Zhang W, Wu Z, et al.  (2021). Baicalin and the liver-gut system: pharmacological bases explaining its therapeutic effects. Pharmacol Res
165:105444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33493657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Z, Guo L, Huang L, et al.  (2021). Baicalin-loaded macrophage-derived exosomes ameliorate ischemic brain injury via the antioxidative pathway. Mater Sci Eng C Mater Biol Appl
126:112123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34082940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoshnam SE, Winlow W, Farzaneh M, et al.  (2017). Pathogenic mechanisms following ischemic stroke. Neurol Sci
38:1167–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28417216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JY, Choi WI, Kim YH, Tae G. (2013). Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials
34:1170–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23122677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SM, Park H, Yoo KH. (2010). Synergistic cancer therapeutic effects of locally delivered drug and heat using multifunctional nanoparticles. Adv Mater
22:4049–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20665571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang W, Huang X, Chen W. (2017). The effects of baicalin and baicalein on cerebral ischemia: a review. Aging Dis
8:850–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5758355</ArticleId>
            <ArticleId IdType="pubmed">29344420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Zhang L, He Q, et al.  (2015). Effect of baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats. Int J Pharm
489:131–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25895718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long Y, Yang Q, Xiang Y, et al.  (2020). Nose to brain drug delivery - a promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion. Pharmacol Res
159:104795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32278035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longa EZ, Weinstein PR, Carlson S, Cummins R. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke
20:84–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2643202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorenzano S, Rost NS, Khan M, et al.  (2019). Early molecular oxidative stress biomarkers of ischemic penumbra in acute stroke. Neurology
93:e1288–e1298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7011868</ArticleId>
            <ArticleId IdType="pubmed">31455665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Wang X, Xu T, et al.  (2020). An integrative pharmacology-based analysis of refined qingkailing injection against cerebral ischemic stroke: a novel combination of baicalin, geniposide, cholic acid, and hyodeoxycholic acid. Front Pharmacol
11:519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7227481</ArticleId>
            <ArticleId IdType="pubmed">32457601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins PP, Smyth H, Cui Z. (2019). Strategies to facilitate or block nose-to-brain drug delivery. Int J Pharm
570:118635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31445062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Md S, Alhakamy NA, Aldawsari HM, Asfour HZ. (2019). Neuroprotective and antioxidant effect of naringenin-loaded nanoparticles for nose-to-brain delivery. Brain Sci
9:275.</Citation>
        </Reference>
        <Reference>
          <Citation>Powers WJ, Rabinstein AA, Ackerson T, et al.  (2019). Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke association. Stroke
50: e344–e418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31662037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Said-Elbahr R, Nasr M, Alhnan MA, et al.  (2016). Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer. Eur J Pharm Biopharm
103:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27020529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi K, Tian DC, Li ZG, et al.  (2019). Global brain inflammation in stroke. Lancet Neurol
18:1058–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31296369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Q, Cheng Y, Dong X, et al.  (2020). Effects of rhaponticin on retinal oxidative stress and inflammation in diabetes through NRF2/HO-1/NF-κB signalling. J Biochem Mol Toxicol
34:e22568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32662907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi X, Fu Y, Zhang S, et al.  (2017). Baicalin attenuates subarachnoid hemorrhagic brain injury by modulating blood-brain barrier disruption, inflammation, and oxidative damage in mice. Oxid Med Cell Longev
2017:1401790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5587966</ArticleId>
            <ArticleId IdType="pubmed">28912935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun K, Fan J, Han J. (2015). Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage. Acta Pharm Sin B
5:8–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4629119</ArticleId>
            <ArticleId IdType="pubmed">26579420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Xu L, Du J, et al.  (2021). Nose-to-brain delivery of borneol modified tanshinone IIA nanoparticles in prevention of cerebral ischemia/reperfusion injury. Drug Deliv
28:1363–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8245080</ArticleId>
            <ArticleId IdType="pubmed">34180761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Yu JY, Sun Y, et al.  (2021). Baicalin protects LPS-induced blood-brain barrier damage and activates Nrf2-mediated antioxidant stress pathway. Int Immunopharmacol
96:107725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34162131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Song X, Kebebe D, et al.  (2019). Brain targeting of baicalin and salvianolic acid B combination by OX26 functionalized nanostructured lipid carriers. Int J Pharm
571:118754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31604118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang Y, Long Y, Yang Q, et al.  (2020). Pharmacokinetics, pharmacodynamics and toxicity of Baicalin liposome on cerebral ischemia reperfusion injury rats via intranasal administration. Brain Res
1726:146503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31605698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J, Luo Y, Liu Y, et al.  (2019). Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose-sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin. Int J Nanomedicine
14:353–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6322498</ArticleId>
            <ArticleId IdType="pubmed">30655668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ya BL, Liu Q, Li HF, et al.  (2018). Uric acid protects against focal cerebral ischemia/reperfusion-induced oxidative stress via activating Nrf2 and regulating neurotrophic factor expression. Oxid Med Cell Longev
2018:6069150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6276484</ArticleId>
            <ArticleId IdType="pubmed">30581534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan W, Ren D, Feng X, et al.  (2021). Neuroprotective and anti-inflammatory effect of pterostilbene against cerebral ischemia/reperfusion injury via suppression of COX-2. Front Pharmacol
12:770329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8593399</ArticleId>
            <ArticleId IdType="pubmed">34795593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You L, Wang J, Liu T, et al.  (2018). Targeted brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in Parkinsonian mice. ACS Nano
12: 4123–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29617109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang AP, Zhang YY, Liu AF, et al.  (2020). Molecular mechanism of long-term neuroprotective effects of gradual flow restoration on cerebral ischemia reperfusion injury in MCAO rats. J Stroke Cerebrovasc Dis
29:105041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32807453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Wang J, Pan J. (2016). Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats. Drug Deliv
23: 3696–703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27749105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Chen H, Ding L, et al.  (2021). Trojan horse delivery of 4,4'-dimethoxychalcone for Parkinsonian neuroprotection. Adv Sci (Weinh)
8: 2004555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8097374</ArticleId>
            <ArticleId IdType="pubmed">33977069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Liu S, Wan J, et al.  (2020). Preparation, characterization and in vivo study of Borneol-Baicalin-Liposomes for treatment of cerebral Ischemia-Reperfusion injury. Int J Nanomedicine
15:5977–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7455751</ArticleId>
            <ArticleId IdType="pubmed">32904394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao L, Wei Y, Huang Y, et al.  (2013). Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine
8:3769–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3794992</ArticleId>
            <ArticleId IdType="pubmed">24124365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong ZF, Han J, Zhang JZ, et al.  (2019). Neuroprotective effects of salidroside on cerebral ischemia/reperfusion-induced behavioral impairment involves the dopaminergic system. Front Pharmacol
10:1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6923222</ArticleId>
            <ArticleId IdType="pubmed">31920641</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
